Trial no.:
|
PACTR201705002168252 |
Date of Approval:
|
03/04/2017 |
Trial Status:
|
Retrospective registration - This trial was registered after enrolment of the first participant |
|
TRIAL DESCRIPTION |
Public title
|
Which Is First Argon Laser Therapy Or Intravitreal Bivacizumab In Branch Retinal Vein Occlusion With Macular Oedema. |
Official scientific title |
Which Is First Argon Laser Therapy Or Intravitreal Bivacizumab In Branch Retinal Vein Occlusion With Macular Oedema. |
Brief summary describing the background
and objectives of the trial
|
To compare anatomical and functional efficacy of argon laser therapy followed by intravitreal bivacizumab with intravitreal bevacizumab firstly followed by argon laser therapy for macular edema due to branch retinal vein occlusion (BRVO). |
Type of trial |
CCT |
Acronym (If the trial has an acronym then please provide) |
|
Disease(s) or condition(s) being studied |
Eye Diseases,Macular edema, branch retinal vein occlusion |
Sub-Disease(s) or condition(s) being studied |
|
Purpose of the trial |
Treatment: Other |
Anticipated trial start date |
03/09/2016 |
Actual trial start date |
05/10/2016 |
Anticipated date of last follow up |
10/05/2017 |
Actual Last follow-up date |
12/07/2017 |
Anticipated target sample size (number of participants) |
60 |
Actual target sample size (number of participants) |
50 |
Recruitment status |
Completed |
Publication URL |
|
|